6533b870fe1ef96bd12cfd13

RESEARCH PRODUCT

Prognostic and therapeutic implications of dipyridamole stress cardiovascular magnetic resonance on the basis of the ischaemic cascade

Oliver HusserMaria P. Lopez-lereuDavid MoratalLuis MainarJuan SanchisJosé MilletVicente RuizJulio NúñezVicente BodiÀNgel LlàcerFrancisco J. ChorroEva RumizJose V. Monmeneu

subject

MaleChest Painmedicine.medical_specialtyPerfusion ImagingVasodilator AgentsPerfusion scanningCoronary Artery DiseaseChest painMagnetic resonance angiographyCoronary artery diseaseInternal medicineMyocardial RevascularizationmedicineHumanscardiovascular diseasesmedicine.diagnostic_testbusiness.industryUnstable anginaDipyridamoleMiddle AgedPrognosismedicine.diseaseDipyridamoleExercise TestCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessPerfusionMagnetic Resonance AngiographyMacemedicine.drug

description

To determine the prognostic and therapeutic implications of stress perfusion cardiovascular magnetic resonance (CMR) on the basis of the ischaemic cascade.Single centre study in a teaching hospital in Spain.Dipyridamole stress CMR was performed on 601 patients with ischaemic chest pain and known or suspected coronary artery disease. On the basis of the ischaemic cascade, patients were categorised in C1 (no evidence of ischaemia, n = 354), C2 (isolated perfusion deficit at stress first-pass perfusion imaging, n = 181) and C3 (simultaneous perfusion deficit and inducible wall motion abnormalities, n = 66). CMR-related revascularisation (n = 102, 17%) was defined as the procedure prompted by the CMR results and carried out within the next three months.During a median follow-up of 553 days, 69 major adverse cardiac events (MACE), including 21 cardiac deaths, 14 non-fatal myocardial infarctions and 34 admissions for unstable angina with documented abnormal angiography were detected. In non-revascularised patients (n = 499), the MACE rate was 4% (14/340) in C1, 20% (26/128) in C2 and 39% (12/31) in C3 (adjusted p value = 0.004 vs C2 and0.001 vs C1). CMR-related revascularisation had neutral effects in C2 (20% vs 19%, 1.1 (0.5 to 2.4), p = 0.7) but independently reduced the risk of MACE in C3 (39% vs 11%, 0.2 (0.1 to 0.7), p = 0.01).Dypiridamole stress CMR is able to stratify risk on the basis of the ischaemic cascade. A small group of patients with severe ischaemia-simultaneous perfusion deficit and inducible wall motion abnormalities-are at the highest risk and benefit most from MACE reduction due to revascularisation.

https://doi.org/10.1136/hrt.2007.139683